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Abstract
Current treatments for allergies include epinephrine and anti-histamines which treat the symptoms
after an allergic response has taken place, steroids that result in local and systemic immune
suppression and IgE-depleting therapies which can only be used for a narrow range of clinical IgE
titers. The limitations of current treatments motivated the design of a heterobivalent inhibitor
(HBI) of IgE-mediated allergic responses that selectively inhibits allergen-IgE interactions,
thereby preventing IgE clustering and mast cell degranulation. The HBI was designed to
simultaneously target the allergen binding site and the adjacent conserved nucleotide binding site
(NBS) found on the Fab of IgE antibodies. The bivalent targeting was accomplished by linking a
hapten to an NBS ligand with an ethylene glycol linker. The hapten moiety of HBI enables
selective targeting of a specific IgE while the NBS ligand enhances the avidity for the IgE.
Simultaneous bivalent binding to both sites provided HBI with 120 fold enhancement in avidity
for the target IgE compared to the monovalent hapten. The increased avidity for IgE made HBI a
potent inhibitor of mast cell degranulation in the rat basophilic leukemia (RBL) mast cell model,
in the passive cutaneous anaphylaxis (PCA) mouse model of allergy, and in mice sensitized to the
model allergen. Additionally, HBI did not have any observable systemic toxic effects even at
elevated doses. Taken together, these results establish the HBI design as a broadly applicable
platform with therapeutic potential for the targeted and selective inhibition of IgE-mediated
allergic responses including food, environmental, and drug allergies.
Introduction
Type-1 hypersensitivity results from allergen induced cross-linking of IgE antibodies, bound
to the high affinity receptor FcεRI, on the surface of mast cells (1–3). Cross-linking of the
IgE antibodies initiates an intracellular signaling cascade resulting in degranulation, which
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causes the release of preformed mediators stored in cytoplasmic granules including
vasoactive amines, neutral proteases, proteoglycans, cytokines, and chemokines (4). Current
therapies for allergic responses include epinephrine, anti-histamines, steroids, and IgE-
depleting therapies such as omalizumab. Epinephrine and anti-histamines only treat the
symptoms of IgE-mediated hypersensitivity after allergen exposure and do not prevent an
allergic response. Steroids and IgE-depleting therapies can reduce the severity of an allergic
response but have limitations. The use of steroids results in local and systemic immune
suppression with numerous side effects while IgE-depleting therapies (i.e. omalizumab) can
only be used for a narrow range of clinical IgE titers (5–7). The limitations of current
therapies require the design of more specific treatments of IgE-mediated allergic reactions
that would not result in local or systemic suppression of the immune system.
In this study, we engineered heterobivalent inhibitors (HBI) by utilizing the conserved
nucleotide binding site (NBS) found on the Fab domain of IgE antibodies to competitively
inhibit allergen binding to the IgE antibodies, thereby inhibiting mast cell degranulation.
The HBI was designed to simultaneously bind to the NBS as well as the antigen binding site
that are found in proximity in the Fab domain of antibodies (8–12). This was specifically
accomplished by conjugating a hapten, to model an IgE epitope, to an NBS ligand that
targets the NBS. In our bivalent design, the hapten enabled selective targeting of an IgE,
while the NBS ligand increased the avidity of HBI for the target IgE allowing for the
competitive inhibition of allergen-IgE binding interactions. The bivalent targeting provided
HBI with the enhanced avidity for IgE required to competitively inhibit allergen-IgE
interactions thereby preventing IgE clustering and mast cell degranulation. This study
establishes the HBI design as a novel approach for the selective targeting of IgE antibodies




All ligands were synthesized as previously described in detail (11). Briefly, all ligands were
synthesized using fluorenylmethyloxycarbonyl (Fmoc) chemistry on a solid support.
Residues were activated with O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-
phosphate (HBTU) and N,N-Diisopropylethylamine (DIEA) in DMF for 3 min and coupling
completion was monitored with Kaiser tests. The Fmoc protected residues were deprotected
by 3 exposures to 20% piperidine in DMF for 3 min. The ligands were cleaved from the
solid support by 2 exposures to 92/4/4: trifluoroacetic acid/H2O/triisopropylsilane for 30
min and were purified using RP-HPLC on an Agilent 1200 series system with a semi-
preparative Zorbax C18 column (9.4 mm x 250 mm), using linear solvent gradients of 2.5%
min-1 increments in acetonitrile concentration at 4.0 ml/min flow rate. We monitored the
column eluent with a diode array detector allowing a spectrum from 200 to 400 nm to be
analyzed. The purified product was characterized using a Bruker micrOTOF II mass
spectrometer. The purity of all synthesized ligands was estimated to be >97% by an
analytical injection using the above described HPLC with a Zorbax C18 analytical column
(4.6mm x 150 mm). The calculated exact mass of monovalent NF (C24H41N5O11) was
575.2803 Da; found 576.2884 Da. The calculated exact mass of monovalent IBA
(C37H50N6O7S) was 722.3462 Da; found 723.3416 Da. The calculated exact mass of HBI
(C38H56N6O13) was 804.3905 Da; found 805.4017 Da.
Synthesis of BSA Conjugates
BSA conjugates were synthesized and purified as previously described in detail (11). The
average number of additions of each hapten to BSA was determined spectroscopically by
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analyzing the ratios of absorbance at 280 nm (tryptophan residues in BSA and OVA) to 315
nm for NF and 335 nm for dansyl. NF-BSA had an average of 12 haptens, NF-OVA had an
average of 6 haptens and dansyl-BSA had an average of 14 haptens per BSA.
Fluorescence Quenching Assay
The binding constants of monovalent IBA, monovalent NF, and HBI to IgEDNP were
determined as previously described in detail (11). Briefly, NF and dansyl quench the
fluorescence from the IgEDNP tryptophan residues, occurring at 335 nm, only when the two
molecules are in proximity to each other (<10 nm). The ligands were titrated into a 96 well
plate containing a 200 μL solution of 10 nM IgEDNP in PBS. All experiments were repeated
in at least triplicates.
RBL Degranulation Assay
RBL cells and IgEDNP were kindly provided by Dr. Wilson (University of New Mexico) and
IgEdansyl (clone 27–74) was purchased from BD Biosciences. RBL cells were maintained as
described previously (11). For the degranulation assays, 100 μL of cells were plated at 0.5 x
106 cells/mL in a 96 well plate, and were incubated for 24 hours followed by a two hour
incubation with the indicated IgE antibody. Cells were washed immediately before
experiments and were stimulated with the indicated concentrations of allergen for 60
minutes. When testing the allergy inhibitors, the inhibitor was added to cells 30 minutes
prior to the allergen. Degranulation was detected spectroscopically by measuring the activity
of the granule stored enzyme β-hexosaminidase secreted into the supernatant on the
substrate p-nitrophenyl-N-actyl-β-O-glucosamine. All degranulation assays were repeated in
at least triplicates. In all experiments the IgE concentration was 1 μg/mL.
Animals
C57BL/6 female mice (7–8 weeks) were obtained from Harlan Biosciences (Indianapolis,
IN). Mice were maintained in pathogen-free conditions, and studies were approved by the
Indiana University Institutional Animal Care and Use Committee.
Passive Cutaneous Anaphylaxis (PCA)
PCA was performed as previously described (13). Briefly, mice were injected via
intradermal with PBS (left ear) and 100 ng of IgEDNP (right ear). After 24 hours, mice were
injected intravenously with NF-BSA (100 μg) and the indicated amount of HBI. The
thickness of ears was measured before NF-BSA (0 hour), and at 2 and 4 hour after
challenge. The data was expressed as change in tissue thickness compared with values
before NF-BSA administration. Ear tissue was collected 4 hours after challenge for
histological examination.
Sensitization with NF-OVA
C57BL/6 mice were sensitized with two intraperitoneal injections (0.5 ml) of NF-OVA/alum
(20 μg/2 mg) at one-week interval. Seven days after the last sensitization, mice were
challenged via intradermal injection with 20 μg NF-OVA, 20 μg NF-OVA with 10 nmols
HBI, 20 μg NF-BSA, or 20 μg NF-BSA with 10 nmols HBI. The thickness of ears were
measured before and at 2 hours after challenge. The data was expressed as change in
thickness compared with values before NF-OVA or NF-BSA inoculation. Ear tissue was
collected 2 hours after challenge for histological examination.
Ear histological analysis
Ear biopsies from PCA mice were placed in 10% formalin for 24 hours. Routine histological
techniques were used to paraffin embed ears, and 5-μm sections of whole ears were stained
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with H&E. Quantitative digital morphometric analysis of ear thickness was performed using
the application program ImageJ. A minimum of 10 measurements was analyzed. The same
area for each ear was captured and dermal thickness was calculated in inches per pixel.
Statistics
Statistical significance was determined using the ANOVA followed by Tukey’s test for
multiple comparisons. P ≤ 0.05 was considered statistically significant. Calculations were
performed using the Prism 6.0 software program (GraphPad Software).
Results
Design and Characterization of the HBI
We engineered the HBI to simultaneously bind to the antigen binding site and the adjacent
NBS on an IgE Fab (Figure 1). This was specifically accomplished by conjugating a hapten,
to model an IgE epitope, to an NBS ligand. The hapten portion of HBI enabled targeting of a
specific IgE while the NBS ligand provided increased avidity of HBI for the target antibody,
thereby allowing for the competitive inhibition of allergen-IgE binding interactions.
Additionally, the HBI design targets two nearby sites on the same Fab arm of a single IgE
ensuring that the HBI would not cross-link multiple IgEs and stimulate a degranulation
response. In our previous work we extensively characterized the NBS using a combination
of molecular modeling and experimental approaches and demonstrated that this under-
utilized site is conserved across all immunoglobulins despite being proximal to the
hypervariable region (Figure 1) (9–12). Additionally, our analysis of the NBS revealed that
the conformation of the four residues that make up this site, two tyrosine residues on the
light chain and one tyrosine and one tryptophan on the heavy chain, are also highly
conserved (9, 11). The conservation of the NBS site in immunoglobulins provides a
universal site that can be used to increase the avidity of an appropriately designed HBI to
IgE for competitive inhibition of allergen-IgE interactions.
For an effective HBI design, the affinity of the NBS ligand is a critical factor. If the NBS
ligand has too weak an affinity for the NBS, it will not provide the required enhancement in
avidity for HBI to IgE. Conversely, if the affinity is too high, HBI will bind non-specifically
to all immunoglobulins since the NBS is present on all antibodies. Therefore we predicted
that a moderate affinity of ~1 μM, which is common for interactions between immune
components, would be best suited for this application. In a previous study, we identified
indole-3-butyric acid (IBA) as an NBS ligand by screening a library of ligands and
determined that IBA has an affinity of 1–8 μM for the NBS site depending on the antibody
(11, 12). Therefore, we selected IBA as the NBS ligand in our approach.
The most commonly used allergen-IgE experimental model is the dinitrophenyl/anti-
dinitrophenyl IgE (DNP/IgEDNP) pair (14). In this system mast cells are primed with
monoclonal IgEDNP and stimulated with a multivalent synthetic allergen typically
synthesized by conjugating DNP to BSA (DNP-BSA). The drawback of this system is that
DNP binds to IgEDNP with an atypically high monovalent affinity. Therefore to identify an
alternate hapten to be used as the synthetic allergen as well as the hapten moiety in our HBI
design, we screened a large number of molecules that bind to IgEDNP with a range of
affinities and selected NF as the hapten to develop the HBI and test our hypothesis. NF has
an affinity of 45 μM to IgEDNP providing a hapten with similar affinity as IBA to IgE.
To synthesize the HBI we conjugated NF to IBA with an ethylene glycol linker (Figure 2A).
In our previous studies we have used ethylene glycol extensively as a linker in multivalent
targeting due to its numerous favorable properties including hydrophilicity to improve
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solubility, and flexibility to allow multivalent binding without steric constraints (15–20).
Moreover, ethylene glycol does not form non-specific interactions with proteins. The
binding affinities of monovalent IBA, monovalent NF, and HBI for IgEDNP were
determined using a fluorescence quenching technique as described in the Materials and
Methods. NF quenches the fluorescence of tryptophan residues in the IgE antibody when in
close proximity (<10 nm) allowing the affinity of NF and HBI to be determined directly.
IBA does not quench tryptophan fluorescence so the monovalent IBA ligand was
synthesized incorporating the dansyl moiety which quenches tryptophan fluorescence
(Figure 2A). In a control experiment we demonstrated that dansyl does not bind to IgEDNP
(data not shown). The binding affinities of monovalent IBA, monovalent NF, and HBI for
IgEDNP were found to be 4.3 ± 0.6 μM, 45 ± 5 μM, and 0.375 ± 0.04 μM respectively
(Figure 2B). The bivalent targeting strategy provided HBI with a 120 fold increase in avidity
for IgEDNP compared to monovalent NF and greater than 11 fold increase in avidity for
IgEDNP compared to monovalent IBA (Figure 2B). Combined these results indicate the
potential of HBI to inhibit allergen binding and prevent mast cell degranulation.
Evaluation of HBI using the in vitro RBL Mast Cell Model
Multivalent allergens mediate clustering of FcεR1-IgE protein complexes on the surface of
mast cells stimulating an allergic response. A multivalent allergen was modeled by
conjugating multiple copies of NF to BSA resulting in the synthetic allergen NF-BSA with
an average of 14 NF moieties per BSA. The RBL-2H3 cell line is the most commonly used
cell line in inflammation, allergy, and immunological research and has been shown to be a
suitable model system for mast cell degranulation (14, 21–23). Thus, to assess the potential
of HBI to inhibit mast cell degranulation we first utilized the well-established, histamine
releasing, RBL-2H3 cell line as our mast cell model. First the cells were incubated with
IgEDNP to allow the antibody to bind to the FcεR1 receptor on the surface of the cells. Next
the cells were exposed to increasing concentrations of NF-BSA to crosslink the surface
bound IgEDNP and stimulate degranulation. NF-BSA stimulated a dose dependent response
from 1 μg/mL to 100 μg/mL with near maximal response occurring at 10 μg/mL (Figure
3A). The ability of NF-BSA to stimulate degranulation was significant. The most commonly
used synthetic allergen is DNP conjugated to BSA (DNP-BSA). The hapten DNP has a high
affinity for IgEDNP while NF has a relatively weak affinity for the same antibody.
Consequently, degranulation stimulated by NF-BSA demonstrated the significance of low
affinity epitopes in allergy while at the same time providing a suitable experimental model
to evaluate the HBI design.
Next, HBI was evaluated by exposing RBL cells primed with IgEDNP to 10 μg/mL NF-BSA
with increasing concentrations of HBI. Based on these results, HBI completely inhibited the
degranulation response with an IC50 of 13.6 μM (Figure 3B). To demonstrate the
significance and necessity of the heterobivalent targeting strategy to inhibit allergen binding,
we repeated the same assay using monovalent NF or monovalent IBA in place of HBI.
Neither monovalent NF nor monovalent IBA were able to inhibit degranulation at
concentrations up to 200 μM (Figure 3B, Figure S1). These results highlight the importance
of the enhancement in avidity for IgE obtained with the heterobivalent design. It is important
to note that maximum degranulation can occur with as little as 1%–10% of the surface
bound IgE cross-linked (24). This means that greater than 90% of the allergen IgE
interactions must be inhibited before there is a decrease in the degranulation response thus
explaining an IC50 greater than the Kd. In a separate control experiment we synthesized and
tested a molecule identical to HBI except the IBA moiety was replaced with dansyl, a
structurally similar molecule to IBA, but has no detectable affinity for the NBS. As
expected, this molecule did not inhibit mast cell degranulation (Figure S1). Combined these
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results demonstrated that both the NF and IBA moieties were necessary for efficient
inhibition of mast cell degranulation.
Finally to demonstrate the specificity of HBI for IgEDNP, the RBL cells were primed with
IgEdansyl then stimulated with the allergen dansyl-BSA. Dansyl-BSA, similar to NF-BSA,
stimulated a dose dependent degranulation response (Figure S2A). RBL cells, primed with
IgEdansyl were incubated with dansyl-BSA and increasing concentrations of HBI. As
expected HBI did not inhibit degranulation stimulated by dansyl-BSA (Figure S2B)
highlighting the specificity of HBI for IgEDNP.
Assessment of HBI Toxicity in vivo
As the next step in evaluating the therapeutic potential of the HBI design, we evaluated the
toxic effects of the HBI on C57BL/6 mice. The acute and chronic systemic toxicity of HBI
was assessed by a single intravenous injection of HBI at 1, 10, and 30 nmol per mouse at 3
days and 14 days after administration, respectively. The dose of HBI, 1, 10, and 30 nmol per
mouse were selected based on the in vitro inhibition data and correspond to initial blood
concentrations of 1 – 30 μM (1 mL per mouse) approximating the concentration required to
inhibit mast cell degranulation in vitro. The body weights of mice receiving the HBI
injection were monitored every 2 or 3 days for 14 days and did not vary significantly from
the control group (Figure 4A). Additionally, mice were sacrificed at 3 and 14 days after HBI
injection and organ weight and blood counts were analyzed to determine any specific
toxicity. As shown in Figure 4, even the highest dose of HBI did not cause any change in
liver, kidney, spleen, heart, liver, lung, or brain organ weights at 3 or 14 days post injection.
Additionally, the white blood cell count, red blood cell counts, and platelets remained
unchanged from the control group both 3 and 14 days post HBI injection. Combined these
results demonstrate the HBI to be well tolerated in vivo thus demonstrating the potential of
the HBI design for the specific inhibition of IgE-mediated allergic responses.
Evaluation of HBI using in vivo PCA Mouse Model of Allergy
To determine whether HBI has an in vivo inhibitory effect on mast cell degranulation, we
selected the well-established passive cutaneous anaphylaxis (PCA) mouse model of allergy
(13). Before evaluating the HBI, it was first necessary to determine if the weak affinity
allergen, NF-BSA, was capable of stimulating a degranulation response in vivo. To assess
NF-BSA, C57BL/6 mice were injected intradermally with PBS (left ear) and 100 ng of
IgEDNP (right ear), and after 24 hours, mice were challenged intravenously with 100 μg of
NF-BSA. The severity of the allergic reaction was quantified by comparing the tissue
thickness of the ear that received the IgE injection to the ear that received the PBS injection
using both micrometer measurements and histology. As observed in Figure 5A, NF-BSA
significantly increased tissue swelling at 2 and 4 hours after challenge, when compared with
the control group. Mice treated with DNP-BSA were used as a control and showed a similar
increase in ear thickness (data not shown). Next we investigated the inflammatory response
induced by NF-BSA. Histopathological analysis of ear sections did not show an increase in
inflammatory infiltrate after NF-BSA injection indicating that the observed edema is caused
by the release of inflammatory mediators from mast cells in the tissue. Morphometric
analysis of ear sections confirmed the effects of NF-BSA on ear swelling as indicated in
Figure 5B and C. The in vivo mast cell degranulation response elicited by NF-BSA mirrored
the in vitro degranulation results and demonstrated the suitability of the PCA model for the
evaluation of HBI.
Next, HBI was evaluated using the described PCA mouse model by challenging C57BL/6
mice intravenously with 100 μg of NF-BSA with the indicated amount of HBI. The amounts
of HBI, 0.5, 5, and 10 nmols per mouse were selected based on the in vitro inhibition data
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and correspond to initial blood concentrations of 0.5 – 10 μM (1 mL per mouse)
approximating the range where inhibition was observed in vitro. At 2 hours after challenge,
5 and 10 nmol of HBI significantly inhibited ear swelling when compared to non-treated
mice. Four hours after challenge, the highest concentration of HBI significantly inhibited ear
edema, while a partial decrease in ear thickness was observed with 0.5 and 5 nmol of HBI
treatment (Figure 5A). The decreased edema observed with HBI treatment was confirmed by
analyzing the inflammatory response by histopathological and morphometric analysis of ear
sections. Ear sections from mice treated with 10 nmol of HBI showed significantly
decreased ear thickness while mice treated with 0.5 and 5 nmol showed partially decreased
ear thickness (Figure 5B and C). Thus, these results indicate that HBI blocks the effects of
NF-BSA on tissue inflammation and edema induced by mast cell degranulation and
demonstrates the therapeutic potential of the HBI design.
HBI Decreases Immediate Hypersensitivity Following Allergen Sensitization
In an active allergic response polyclonal IgE antibodies bind to multiple epitopes on the
allergen with a wide range of affinities. In addition, there may be allergen specific IgG and
IgA antibodies that could bind and sequester the HBI, prevent it from reaching its target IgE
antibody and inhibiting the degranulation response. Therefore, to demonstrate the clinical
relevance of HBI design, mice were sensitized with NF conjugated OVA (NF-OVA)
adsorbed to alum (Figure 6A). NF-OVA sensitized mice were challenged intradermally with
NF-OVA, NF-OVA + HBI, NF-BSA, or NF-BSA + HBI and ear swelling was determined 2
hours after challenge. Mice challenged with NF-OVA experienced a significant increase in
ear swelling which was significantly reduced when NF-OVA was co-administered with HBI
(Figure 6B). The reduction in ear swelling, as a result of inhibition by HBI, was not as
dramatic as in the PCA allergy model where complete inhibition was observed. In the PCA
allergy model, mice were sensitized via intradermal injection with IgEDNP ensuring high
specificity to the NF hapten whereas in the active allergic response it is likely that there
were IgE antibodies specific for epitopes on the surface of OVA that did not include the NF
hapten. HBI would not inhibit IgE antibodies from binding to these epitopes as it was
specifically designed to inhibit the NF-IgE interactions.
Interestingly, NF-BSA caused only a minimal increase in ear swelling (Figure 6B). This
result indicates that the IgE epitopes likely include residues of OVA adjacent to the
conjugation sites of NF in addition to the NF hapten such that the IgE antibodies had a very
low affinity for the NF hapten alone and due to this low affinity no significant response was
observed. As expected, mice treated with NF-BSA + HBI did not display any significant
allergic response. Since mice treated with NF-BSA alone or in combination with HBI did
not experience increased edema this demonstrated that HBI alone did not cause any damage
to the ear tissue. Histopathological analysis of the ear tissue revealed an inflammatory
infiltrate composed of cells with the morphological characteristics of eosinophils in mice
challenged with NF-OVA (Figure 6C). NF-OVA also resulted in increased dermal and
epidermal thickening when compared to mice challenged with NF-BSA (Figure 6C). Co-
injection of NF-OVA with the HBI limited the inflammatory cell infiltrate and the dermal
and epidermal thickening (Figure 6C). Combined, these results demonstrate that an injection
of an HBI specific for an allergen epitope can block an active allergic response in vivo.
Discussion
In this study we designed HBIs to simultaneously target the antigen binding site and the
NBS on an IgE Fab to competitively inhibit allergen-IgE interaction on the mast cell surface,
thereby preventing mast cell degranulation. The bivalent targeting strategy provided HBI
with 120 and 11 fold increased avidity for IgEDNP compared to monovalent NF and
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monovalent IBA, respectively. The increased avidity of HBI competitively inhibited
allergen binding and prevented mast cell degranulation in vitro and in passive and active in
vivo allergy models, establishing the HBI design as a potential therapeutic approach in
selective inhibition of IgE-mediated allergic responses.
There are a number of important considerations in moving the HBI design forward as a
potential therapeutic strategy. We observed no indication of systemic toxicity over the
concentration range required for effective inhibition of the degranulation response, though
further studies would be required to eliminate more subtle effects on specific organ systems.
Although the short time frame for these studies precludes the generation of an immune
response to the HBI, a therapeutic application may require repeated administration and
would therefore have the potential for an anti-drug response by the recipient. However, the
main component of the HBI is an ethylene glycol linker and ethylene glycol is commonly
used in liposomal drug delivery to provide “stealth” from the recipient immune system.
Thus, we do not expect a significant response to develop, even after repeated exposure. The
half-life of the HBI will also be important to consider. The HBI design enables bivalent
targeting for allergen-specific IgE antibodies with high affinity and specificity. However, the
NBS is present on all immunoglobulins causing the HBI to interact weakly with all
antibodies and this weak association may act to increase the circulation half-life of the HBI.
Further studies are required to determine what effect this will have on the circulation half-
life of the HBI.
The non-specific interaction of the HBI to all immunoglobulins through the NBS could
prevent the HBI from binding to the target IgE. However our design circumvented this
problem by using a NBS ligand with moderate affinity for the NBS (~1 μM). If the NBS
ligand bound too tightly to this site, the majority of the HBI would be sequestered by other
immunoglobulins present in the physiological system and would not reach the target IgE.
Conversely, if the NBS ligand bound too weakly, it would not bring the significant
enhancement in avidity required for the competitive inhibition of allergen-IgE interactions.
We attribute the enhanced avidity and selectivity of HBI to result from the increased
effective concentration of the binding moieties (11, 25, 26). When the first component of
HBI binds to IgE, either the hapten or the NBS ligand, the second component is held in close
proximity to the IgE raising the effective ligand concentration resulting in increased avidity.
This principle ensures that the HBI will selectively and exclusively bind to the target IgE
with a high affinity, in an allergen specific manner, as the target IgE is the only
macromolecule present in biological systems with both the NBS and the specific antigen
binding site. Our results confirmed our prediction that an NBS ligand with a moderate
affinity would be best suited for the HBI design as was demonstrated by the efficient
inhibition of mast cell degranulation in vivo. Additionally, the HBI was well tolerated and
no systemic toxicity was observed in vivo over the concentration range required for effective
inhibition of a degranulation response.
This study demonstrates the potential of the HBI design to selectively inhibit allergen-IgE
interactions, which is the key event in initiating an allergic response. Current treatments for
allergies either only treat the symptoms following allergen exposure, cause local or systemic
suppression of the immune system to decrease the severity of an allergic response, or are
only available to patients with a narrow range of IgE titers and are very expensive. The
results presented in this study demonstrate that the HBI design has the potential to address
the limitations of current therapies by selectively inhibiting mast cell degranulation in an
allergen specific manner. In addition, the concepts presented in this study establish a utility
for the conserved NBS found on immunoglobulins in selective inhibition of IgE-mediated
allergic responses. Importantly, this approach has broad implications in inhibiting drug
allergies, food allergies, environmental allergies, and asthmas where the allergy epitopes are
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known. As an example β-lactam antibiotics and the class of sulfonamide drugs are well-
defined small molecules, which frequently cause allergic reactions. These small molecules
can be readily incorporated in the HBI design for use as the hapten portion of HBI thus
allowing the specific inhibition of drug allergies. Food and environmental allergens are
structurally more complex, however, increasing amounts of knowledge on these allergens
are becoming available due to technological advances in epitope mapping techniques and
the establishment of centralized databases such as the Immune Epitope Database (27). For
these types of allergens, short peptide sequences that mimic the IgE epitope can be used as
the hapten portion of the HBI design allowing for the specific and widespread use of the
HBI design to prevent IgE-mediated allergy.
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Heterobivalent targeting strategy. Representative crystal structure of an IgG antibody (to
model IgE) and an enlargement of the Fab region with the antigen binding site and the
nucleotide binding site (NBS) identified. The heterobivalent inhibitor (HBI) was designed to
simultaneously bind to the antigen binding site and the NBS on an IgE.
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Chemical structures and affinities for IgEDNP. (A) Structures of monovalent nitro furan
(NF), monovalent indole butyric acid (IBA), and heterobivalent inhibitor (HBI). (B) Binding
curves for HBI, monovalent IBA, and monovalent NF to IgEDNP. Binding was observed by
monitoring the fluorescence quenching of the tryptophan residues in the IgE antibodies
caused by NF or dansyl. Values for the binding constants are Kd,HBI = 0.375 ± 0.04 μM,
Kd,IBA = 4.3 ± 0.6 μM, and Kd,NF = 45 ± 5 μM. Data represents the mean ± standard
deviation of triplicate experiments.
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Effect of HBI on RBL mast cell degranulation. (A) Dose response of RBL mast cell
degranulation in response to increasing concentrations of NF-BSA. (B) Inhibition of RBL
mast cell degranulation by HBI (○) and monovalent NF (□). The indicated concentration of
inhibitor was added to the cells 30 minutes prior to the addition of 10 μg/mL NF-BSA.
Triton X-100 (1%) was used to lyse cells and determine maximum response. Data represents
the mean ± standard deviation of triplicate experiments.
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Assessment of HBI toxicity in vivo. (A) Percentage of body weight of C57BL/6 mice
intravenously injected with HBI as a measure of systemic toxicity. (B) Organ weight of mice
sacrificed 3 or 14 days after receiving a single intravenous injection of HBI as a measure of
specific toxicity. (C) Blood counts from mice receiving a single intravenous injection of
HBI. Data represents the mean ± SEM of 6 mice per group.
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Effects of HBI on passive cutaneous anaphylaxis in C57BL/6 mice. (A) Ear swelling during
PCA was determined after 2 and 4 hours of systemic NF-BSA challenge in mice receiving
no treatment or 0.5, 5, and 10 nmol of HBI. (B) Ear tissue was stained with H&E at 4 hours
after systemic challenge. Representation of dermal thickness in control and NF-BSA
challenged mice is shown at original magnification, x100. (C) Morphometric analysis of
changes in dermal thickness was performed. Data represents the mean ± SEM of 5 mice
from two independent experiments. *p<0.05.
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Effects of HBI in an active allergic response in C57BL/6 mice. (A) C57BL/6 mice were
sensitized twice with two intraperitoneal injections of NF-OVA absorbed to alum at one-
week intervals. Seven days after the last sensitization, mice were challenged via intradermal
injections. (B) Ear swelling was measured two hours after challenge with 20 μg NF-OVA,
20 μg NF-OVA + 10 nmol HBI, 20 μg NF-BSA, or 20 μg NF-BSA + 10 nmol HBI and
compared to values prior to the administration of the synthetic allergens. (C) Ear tissue was
stained with H&E at 2 hours after challenge and the scale bar represents 200 μm top row and
50 μm bottom row. Arrows indicate cells with morphological characteristics of eosinophils.
Data represents the mean ± SEM of 5 mice from 3 independent experiments. *p<0.05.
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